论文部分内容阅读
新辅助化疗在治疗浸润肌层膀胱癌中的应用目前还存在争议。以顺铂为基础的联合新辅助化疗被考虑作为那些浸润肌层或局限晚期,但仍是可手术患者的一种标准治疗。那些不合适或拒绝做根治性膀胱切除术的患者,新辅助化疗联合或不联合放疗可使保留膀胱的患者获得很好的临床疗效。现主要综述局限晚期膀胱癌患者新辅助化疗的研究进展。
The use of neoadjuvant chemotherapy in the treatment of myometrial invasion is still controversial. Cisplatin-based neoadjuvant chemotherapy is considered as a standard treatment for those who have infiltrated the muscle or are late-stage but are still operable. Those who are inappropriate or refuse to do radical cystectomy patients, neoadjuvant chemotherapy with or without radiotherapy can keep the bladder in patients with good clinical results. Now the main review of the limitations of neoadjuvant chemotherapy in patients with advanced bladder cancer.